IQ EQ FUND MANAGEMENT IRELAND Ltd Takes Position in Twist Bioscience Co. (NASDAQ:TWST)

IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 8,153 shares of the company's stock, valued at approximately $402,000.

Several other institutional investors have also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC acquired a new stake in Twist Bioscience in the second quarter worth about $4,150,000. Calamos Advisors LLC acquired a new stake in shares of Twist Bioscience during the 2nd quarter worth approximately $281,000. EdgeRock Capital LLC bought a new stake in shares of Twist Bioscience during the second quarter worth approximately $43,000. Nisa Investment Advisors LLC lifted its holdings in Twist Bioscience by 31.3% in the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company's stock valued at $113,000 after buying an additional 546 shares during the period. Finally, Blue Trust Inc. lifted its holdings in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock valued at $58,000 after buying an additional 1,136 shares during the period.

Insiders Place Their Bets

In related news, COO Patrick John Finn sold 2,207 shares of the stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $56.62, for a total transaction of $124,960.34. Following the completion of the transaction, the chief operating officer now directly owns 171,212 shares in the company, valued at $9,694,023.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Twist Bioscience news, COO Patrick John Finn sold 2,207 shares of the company's stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $56.62, for a total transaction of $124,960.34. Following the completion of the transaction, the chief operating officer now owns 171,212 shares of the company's stock, valued at approximately $9,694,023.44. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Dennis Cho sold 709 shares of the firm's stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $28,310.37. Following the transaction, the insider now directly owns 78,996 shares of the company's stock, valued at $3,154,310.28. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,327 shares of company stock worth $978,760. Corporate insiders own 3.92% of the company's stock.

Twist Bioscience Stock Down 3.7 %

Shares of TWST traded down $1.66 on Friday, hitting $43.24. The company's stock had a trading volume of 1,057,596 shares, compared to its average volume of 1,016,874. The firm's fifty day moving average price is $49.17 and its 200-day moving average price is $42.59. Twist Bioscience Co. has a fifty-two week low of $14.42 and a fifty-two week high of $60.90. The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of -12.87 and a beta of 1.80.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The company had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. During the same quarter last year, the company earned ($1.01) EPS. The firm's quarterly revenue was up 27.7% compared to the same quarter last year. As a group, equities analysts predict that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on TWST. Barclays dropped their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 5th. Robert W. Baird increased their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a research note on Monday, August 5th. JPMorgan Chase & Co. boosted their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a research report on Monday, August 5th. Evercore ISI upped their price target on Twist Bioscience from $46.00 to $50.00 and gave the company an "outperform" rating in a research note on Friday, May 3rd. Finally, The Goldman Sachs Group lifted their price objective on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, July 9th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and a consensus price target of $48.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.